Literature DB >> 27847303

SUMOylation of large tumor suppressor 1 at Lys751 attenuates its kinase activity and tumor-suppressor functions.

Liu Mei1, Lianwen Yuan2, Wei Shi1, Shihao Fan1, Chao Tang1, Xueying Fan1, Wanlei Yang3, Yu Qian3, Musaddique Hussain1, Ximei Wu4.   

Abstract

Large tumor suppressor (Lats) plays a critical role in maintaining cellular homeostasis and is the core to mediate Hippo growth-inhibitory signaling pathway. SUMOylation is a reversible and dynamic process that regulates a variety of cell functions. Here, we show that SUMOylation of Lats1 affects its kinase activity specifically towards Hippo signaling. Small ubiquitin-like modifier (SUMO) 1 interacts with and directly SUMOylates Lats1, whereas loss of SUMOylation pathway function disrupts Lats1 SUMOylation. Among potential SUMOylation sites on hLats1, K751 and K830 are conversed and essential for maintaining the transcriptional output of Hippo signaling, whereas K751 mutation more significantly abolishes SUMO1-induced Lats1 SUMOylation than K830 mutation. Though Lats1 SUMOylation at K751 affects neither its subcellular distribution nor its interactions with YAP and TAZ, it significantly destabilizes the phosphorylated Lats1 (Thr1079 but not Ser909), resulting in the attenuation of Lats1 kinase activity and inhibition of Hippo signaling. Moreover, HepG2 hepatocellular carcinoma cells express significantly more SUMOylated Lats1 than LO2 normal human hepatic cells, and in HepG2 cells or HepG2 cells xenografts, Lats1 SUMOylation at K751 consistently attenuates Lats1 kinase activity and subsequently suppresses Hippo signaling, resulting in not only the promotion of cell proliferation and colony formation but also the suppression of cell apoptosis. Together, we demonstrate that Lats1 SUMOylation at K751 suppresses its kinase activity and subsequently attenuates its tumor-suppressor functions. Thus, this study provides additional insight into how Hippo signaling is regulated and highlights the potentially critical role of Lats1 SUMOylation in tumor development.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hippo signaling; Lats1; SUMOylation; Tumor suppressor

Mesh:

Substances:

Year:  2016        PMID: 27847303     DOI: 10.1016/j.canlet.2016.11.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Verteporfin induced SUMOylation of YAP1 in endometrial cancer.

Authors:  Bo Wang; Wenyu Shao; Yue Shi; Jiongbo Liao; Xiaojun Chen; Chao Wang
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

Review 2.  Targeting the Hippo pathway in heart repair.

Authors:  Fansen Meng; Bing Xie; James F Martin
Journal:  Cardiovasc Res       Date:  2022-08-24       Impact factor: 13.081

3.  Quantitative Analysis of Ubiquitinated Proteins in Human Pituitary and Pituitary Adenoma Tissues.

Authors:  Shehua Qian; Xiaohan Zhan; Miaolong Lu; Na Li; Ying Long; Xuejun Li; Dominic M Desiderio; Xianquan Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-22       Impact factor: 5.555

4.  Suppression of VEGFD expression by S-nitrosylation promotes the development of lung adenocarcinoma.

Authors:  Qiangqiang He; Meiyu Qu; Tingyu Shen; Yana Xu; Jiahao Luo; Dan Tan; Chengyun Xu; Muhammad Qasim Barkat; Ling-Hui Zeng; Ximei Wu
Journal:  J Exp Clin Cancer Res       Date:  2022-08-08

Review 5.  Posttranslational control of lipogenesis in the tumor microenvironment.

Authors:  Yahui Zhu; Xingrong Lin; Xiaojun Zhou; Edward V Prochownik; Fubing Wang; Youjun Li
Journal:  J Hematol Oncol       Date:  2022-08-29       Impact factor: 23.168

6.  SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling.

Authors:  Liu Mei; Meiyu Qv; Hangyang Bao; Qiangqiang He; Yana Xu; Qin Zhang; Wei Shi; Qianlei Ren; Ziyi Yan; Chengyun Xu; Chao Tang; Musaddique Hussain; Ling-Hui Zeng; Ximei Wu
Journal:  Oncogene       Date:  2021-07-15       Impact factor: 9.867

7.  α-catenin SUMOylation increases IκBα stability and inhibits breast cancer progression.

Authors:  Huan Chen; Zhaowei Xu; Xiahui Li; Yangyang Yang; Bowen Li; Yanan Li; Kangkai Xia; Jian Wang; Shujing Li; Miao Wang; Huijian Wu
Journal:  Oncogenesis       Date:  2018-03-13       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.